CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2123 Placebo (Methylcellulose) capsule Wiki 0.71
drug2893 The usual treatment Wiki 0.71
drug3422 pregnant women with laboratory-confirmed 2019-n-CoV Wiki 0.50

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.08
D018352 Coronavirus Infections NIH 0.06
D011014 Pneumonia NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.04

There are 2 clinical trials

Clinical Trials

1 Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients

The leading cause of death in patients with COVID19 is a severe inflammatory response caused by a cytokine storm that results in acute respiratory distress syndrome and acute pulmonary insufficiency, as well as dysfunction of several vital organs. Therefore, preventing the occurrence of uncontrolled inflammation is the main goal of the ongoing clinical trials. Chloroquine and tocilizumab, which have the best results, are also prescribed to control inflammation. But it can be said that treatments are the main source of inflammation. Inflammasome NLRP3 is one of the mechanisms involved in many severe inflammatory disorders. Inflammatory activation has already been demonstrated by many viruses. Melatonin, on the other hand, is a hormone in the body that can inhibit Inflammation NLRP3 in addition to various anti-inflammatory effects, especially after severe inflammation. Older adults with lower levels of melatonin and children with maximum levels of melatonin are the risk groups and low-risk groups for the disease, respectively. In the present study, while measuring melatonin in patients with COVID19, its effectiveness as a treatment method along with the common antiviral drug regimen in patients with severe disease will be evaluated.

NCT04409522 COVID-19 Drug: Melatonin Drug: The usual treatment

Primary Outcomes

Description: Immune system modulator. The amount of it is determined by laboratory methods

Measure: Melatonin

Time: up to 10 days

Secondary Outcomes

Description: is a type of signaling molecule (a cytokine) that is secreted from immune cells like helper T cells (Th) and macrophages, and certain other cell types that promote inflammation which is measured by serological or analyzer method

Measure: Inflammatory cytokines

Time: up to 10 days

Description: C-reactive protein (CRP) is a protein made by the liver that measured by serological or analyzer method

Measure: C-reactive protein (CRP)

Time: up to 10 days

Description: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions that measured by Physical examination.

Measure: Cough

Time: up to 10 days

Description: Oxygen saturation of the blood will measure by pulse oximeter

Measure: Oxygen saturation of the blood

Time: up to 10 days

Description: Red blood cell sedimentation rate will measure by Autoanalyzer

Measure: ESR

Time: up to 10 days

Description: Radiological Treatment Response (CT scan), more than 50% reduction in the affected area

Measure: Radiological Treatment Response

Time: up to 10 days

Description: Cellular pathway active in inflammation

Measure: Inflammatory route

Time: up to 10 days

2 A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection

This study is a pilot randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin in adult outpatients suspected to be afflicted with COVID-19.

NCT04474483 COVID-19 Drug: Melatonin Other: Placebo (Methylcellulose) capsule

Primary Outcomes

Description: Evaluate the incidence of serious adverse effects and discontinuation secondary to toxicity through 28 days of follow-up as compared to the control arm as assessed by: Cumulative incidence of serious adverse events (SAEs), Cumulative incidence of Grade 3 and 4 adverse events (AEs), Discontinuation or temporary suspension of the investigational medication (for any reason).

Measure: Cumulative Incidence of Treatment-Emergent Adverse Events

Time: 28 days

Secondary Outcomes

Description: Incidence of COVID-19 related hospitalization at 28 days

Measure: Hospitalization

Time: 28 days

Description: COVID-19 related symptoms (Fever, chills, cough, nasal symptoms, body aches/muscle aches, headache, loss of smell, loss of taste, nausea, vomiting, diarrhea, fatigue, dizziness) that are self-reported and on interview.

Measure: COVID-19 related symptoms

Time: 28 days

Description: Change from baseline (day 1) as assessed to days 3, 7, 14, and 28

Measure: Rate of resolution of COVID-19 related symptoms

Time: 28 days

Description: 28-day mortality

Measure: Mortality

Time: 28 days

No related HPO nodes (Using clinical trials)